Board of Directors

William Garner, MD

Chairman of the Board of Director

Dr. Garner is a biotech industry entrepreneur with over 25 years’ experience. In 2002 he founded EGB Ventures, where he is focused on advancing technologies and companies to significant value inflection points, leading to monetization of assets via licensing, M&A or IPO transactions.

Dr. Garner served as Non-Executive Chairman & Founder of Race Oncology from 2016 to 2020 and as Founder and Chairman at Isla Pharmaceuticals from 2017 to 2020. He is currently a Founder & Director of Tryp Therapeutics. In addition, he has held Chief Executive Officer positions with a public company in the U.S. and a public company in Australia. Dr. Garner brings additional medical affairs experience from his tenure at Hoffmann LaRoche’s oncology division in 1999. Prior to Roche, Dr. Garner was a healthcare merchant banker in New York City. He has a Master of Public Health from Harvard and earned his M.D. at New York Medical College. Dr. Garner trained in Anatomic Pathology at Columbia-Presbyterian and is currently a licensed physician in the State of New York. Dr. Garner makes valuable contributions to the Board based on his extensive director-level and executive-management experience, as well as his medical background. Mr. Garner has been a director of InMed since June 2016.

Learn More

Catherine A. Sazdanoff, JD

Director

Ms. Sazdanoff is a 35-year veteran of the global pharmaceutical industry and currently serves as President and CEO of Sazdanoff Consulting LLC, which she founded in 2014, where she works with healthcare companies on strategy and corporate development.

Prior to Sazdanoff Consulting, Ms. Sazdanoff held various global VP roles in corporate development and finance at Takeda Pharmaceuticals, where she joined in 2006. Prior to joining Takeda, Ms. Sazdanoff served in senior management positions at Abbott Laboratories since 1984, including international commercial and transactional legal roles, marketing, and business development.

At both Takeda and Abbott, she completed numerous transformational deals, including Abbott’s acquisition of Knoll and Humira®, and Takeda’s acquisitions of Millennium and Nycomed. Ms. Sazdanoff is Board member of Meridian Bioscience. She earned a BA degree from the University of Notre Dame and a JD degree from Northwestern University School of Law.

Learn More

Adam Cutler

Director

Mr. Cutler has over 20 years of experience in the global healthcare industry where he successfully held senior leadership positions in various roles from Equity Research, Corporate Affairs and Strategy, Investor Relations and Consulting.

Mr. Cutler is currently Chief Financial Officer at Molecular Templates, Inc. Previously, he was Senior Vice President of Corporate Affairs at Arbutus Biopharma and, prior to that, was Managing Director at The Trout Group LLC and Trout Capital LLC, where he executed financings and advised a wide range of life science companies on investor relations, business development, and capital raising strategy. Mr. Cutler spent almost 12 years as a sell-side analyst with firms including Credit Suisse, Canaccord Genuity, JMP Securities, and Bank of America Securities, with prior analytical and consulting experience at The Frankel Group and Ernst & Young, Healthcare Consulting. Mr. Cutler holds a BA in Economics from Brandeis University.

Mr. Cutler previously served as a Director of Navidea Biopharmaceuticals, Inc.

Learn More

Andrew Hull, BA

Director

Mr. Hull has over 30 years of experience in various commercial and business development roles with leading pharmaceutical and biotech companies. He most recently served as Vice President of Global Alliances for Takeda Pharmaceuticals where he was responsible

for maximizing the success of Takeda’s growing number (40+) of commercial and R&D partnerships with many of the industry’s leading pharmaceutical and biotech companies. In previous roles, he led marketing and commercial development of Takeda’s United States portfolio of over $3 billion, including diabetes, neuroscience, gastrointestinal and cardiovascular therapies. Additionally, he held positions of increasing responsibility at Immunex and Abbott Laboratories.

Mr. Hull received a bachelor’s degree in biology from Kenyon College in 1985. He also recently served as a member of the Board of Directors of the Illinois Biotechnology Industry Organization and recently was a member of the Kenyon College Board of Trustees. Mr. Hull serves as a Director of Zucara Therapeutics, Inc.

Learn More

Eric A. Adams, MIBS

Chief Executive Officer & President

Mr. Adams is a seasoned biopharmaceutical executive with more than 30 years of experience in company and capital formation, global market development, mergers and acquisitions, licensing and corporate governance.

Mr. Adams has been our President and Chief Executive Officer, and a Director, since 2016. He previously served as CEO at enGene Inc. Prior to enGene, he held senior roles in global market development with QLT Inc., Advanced Tissue Sciences Inc., Abbott Laboratories, and Fresenius AG (Germany).

He is a dual citizen of Canada and the United States and holds a Masters of International Business from the University of South Carolina and a Bachelors in Chemistry from the University of Southern Indiana.

Learn More

Overview

Learn More

Management

Learn More

Scientific Advisory Board

Learn More